Stem cell transplantationBMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7258.433 (Published 12 August 2000) Cite this as: BMJ 2000;321:433
- A L Lennard, senior lecturer (A.L.LENNARD@ncl.ac.uk),
- G H Jackson, consultant haematologist
- Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP
- Correspondence to: A L Lennard
Stem cell transplantation is a generic term covering several different techniques (see fig 1). Allogeneic transplants are haemopoietic stem cells from the bone marrow, peripheral blood, or umbilical cord blood of a healthy donor matched for HLA type, who may be a family member or an unrelated volunteer. Autologous transplants are stem cells from the patient's own bone marrow or peripheral blood.
Allogeneic transplantation was first used to treat congenital immune deficiencies, bone marrow failure, and haematological malignancies and is now used routinely for some non-malignant conditions such as thalassaemia. Autologous transplantation was introduced to rescue the bone marrow of patients due to undergo high dose chemotherapy, and it is now increasingly written into protocols for the primary treatment of solid tumours such as breast cancer and neuroblastoma. Autologous transplantation is also used experimentally to treat difficult autoimmune conditions such as systemic sclerosis and as a vehicle for gene therapy. Knowledge of stem cell transplantation techniques and their clinical application is therefore becoming essential for increasing numbers of medical specialists.
Our review is based on current haematological textbooks, review articles in major haematological journals, and information from recent meetings of learned societies such as the American Society of Haematology and the European Bone Marrow Transplant Society. This review reflects our personal perspectives and is not meant to cover every likely use or possible advance within this rapidly expanding field.
Stem cell transplantation techniques
The first successful bone marrow transplant in humans was performed between identical twins. With a greater understanding of the HLA system, it became possible to perform bone marrow transplants between siblings who were fully HLA identical. Transplantation is widely used for treating congenital bone marrow disorders and malignant haematological diseases. Today, over 350 centres in Europe are performing more than 18 000 bone marrow transplants a year. Centres may report their …